Zepbound will dominate obesity market following SURMOUNT-5 results, says analyst
According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...
Arizona Couple Details 'Life-Changing’ Experience on Weight Loss Drugs — Including ‘Sulphur Burps’
Michael Carroll didn't go out in public and couldn't put on his own socks. Then he and wife Julie began taking a GLP-1 ...
Zacks.com on MSN3hOpinion
5 Large Drug Stocks to Keep An Eye On in the New Year
The drug and biotech industry had a tough time in the past couple of months after Trump announced the appointment of Robert F ...
US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report
Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.
Cases of 'rabbit fever' increase over last decade
Cases of a bacterial infection called "rabbit fever" have been increasing during the past decade, according to the U.S.
Tirzepatide outpacing Wegovy in the obesity space
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...
Why the Obesity Drug Revolution Is a Work in Progress
Kennedy Jr., President-elect Donald Trump’s nominee to head the US Department of Health and Human Services, who has expressed reservations about the pharma industry — and its new wonder drug category.
FiercePharma6h
Lilly’s Zepbound expected to surpass Novo’s Wegovy to ‘dominate’ obesity market: GlobalData
Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on ...